We first wrote about the popular diabetes drug Actos unfortunately being linked to increased risk of bladder cancer last year. You can read that article here.
Since then, numerous lawsuits regarding Actos that were pending in federal courts around the country have been centralized before the Honorable Rebecca F. Doherty in the United States District Court for Western District of Louisiana. The Judicial Panel on Multidistrict Litigation found that the various lawsuits “involve common questions of fact, and that centralization in the Western District of Louisiana will serve the convenience of the parties and witnesses and promote the just and efficient conduct of this litigation.”
The lawsuits all allege claims arising from the use of Actos, a prescription medication approved for use in the treatment of type 2 diabetes. The plaintiffs allege that individuals who use Actos face an increased risk of developing bladder cancer. The plaintiffs further allege that the defendants concealed their knowledge of this risk and failed to provide adequate warnings to consumers and the health care community.
The federal multidistrict litigation (or “MDL”) includes claims arising from ingestion of Actos®, ACTOplus Met®, ACTOplus Met XR®, Duetact®, or pioglitazone.
Judge Doherty has recently ordered that any plaintiff whose case would be subject to transfer to the Actos MDL may file his or her case directly in the MDL Proceedings in the Western District of Louisiana. The order also provides details regarding filing such actions, venue matters as to such actions, and service of process on defendants, including Eli Lilly & Company, Takeda Pharmaceuticals U.S.A., Inc., Takeda Pharmaceuticals America, Inc., Takeda Global Research & Development Center, Inc., Takeda California, Inc., and Takeda Pharmaceuticals International, Inc.
Heygood, Orr & Pearson is pursuing Actos cases on behalf of clients and will be involved closely with the Actos MDL and other Actos bladder cancer litigation matters, so you can expect to find more information here. Of course, feel free to contact us if you have any questions about Actos.